• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioSig to Host Conference Call on December 21, 2021

    12/13/21 8:30:00 AM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BSGM alert in real time by email

    Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET.

    Conference Call Details

    Date: Tuesday, December 21, 2021

    Time: 2:00 PM Eastern Time (ET)

    Dial-in number for US callers (toll-free): 877-407-8293

    Dial-in number for U.S. and international callers (toll): +1 201-689-8349

    To join the conference call online, please click here:

    BioSig Webcast

    A webcast replay will be available two hours after the event's conclusion and archived for six months.

    The PURE EP (tm) is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. Clinical data acquired by the PURE EP (tm) System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP (tm) signals over conventional sources.

    One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually2.

    About BioSig Technologies

    BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. (www.biosig.com).

    The Company's first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. To date, 73 physicians have completed over 1750 patient cases with the PURE EP (tm) system. The Company is in a focused commercial launch of the PURE EP (tm) System in the Northeast, Texas, and Florida. The technology is regularly used in some of the country's highest-ranked hospitals, including St. David's Medical Center in Austin, TX, Mayo Clinic campuses in Florida, Minnesota, and Arizona, and University of Pennsylvania in Philadelphia, PA.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 






    1 Top 10 Things You should Know About Heart Rhythm; Scripps Health.

    2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4





    Andrew Ballou
    BioSig Technologies, Inc. 
    Vice President, Investor Relations 
    54 Wilton Road, 2nd floor
    Westport, CT 06880
    [email protected]
    203-409-5444, x133
    
    

    Primary Logo

    Get the next $BSGM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BSGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BSGM
    Financials

    Live finance-specific insights

    See more
    • BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

      Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

      9/22/22 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig to Host Conference Call on December 21, 2021

      Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

      12/13/21 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

      Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq. Proposed Transaction Highlights include: Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.  Commodity-focused real-world asset

      5/5/25 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

      Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) ("BioSig" or the "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce that its common stock will continue trading on The Nasdaq Capital Market ("Nasdaq"). On March 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC confirming that it has met the required minimum stockholders' equity threshold of $2.5M as outlined in Listing Rule 5550(b). As a result, the Company's previously disclosed deficiency has been resolved, and the Company now remains in full compliance with all applicable Na

      3/26/25 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement

      Los Angeles, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization,  today announced that it has received notice from the Nasdaq Listing Qualifications staff ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). To regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days; on November 13, 2024, Nasdaq informed

      11/13/24 3:14:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on BioSig Technologies with a new price target

      The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

      2/8/21 7:32:50 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BSGM
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      11/14/24 3:58:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioSig Technologies Inc.

      SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      2/14/24 3:31:45 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      7/12/21 8:29:21 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/5/25 9:17:41 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 8-K filed by BioSig Technologies Inc.

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      4/30/25 3:37:34 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      4/28/25 7:51:54 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Leadership Updates

    Live Leadership Updates

    See more
    • BioSig Enters into an LOI to Merge with Streamex Exchange Corp. Creating a Publicly Listed Real-World Asset Tokenization Company Led by Seasoned Industry Executives

      Los Angeles, CA, May 05, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company is pleased to announce it has entered into a Letter of Intent ("LOI") to enter into a proposed merger or other business combination (the "Merger"), with Streamex Exchange Corporation ("Streamex") in an all-stock transaction, to bring a real-world asset tokenization company public on the Nasdaq. Proposed Transaction Highlights include: Technology Stack – A fully developed and operational primary issuance and decentralized exchange infrastructure for on chain commodity markets.  Commodity-focused real-world asset

      5/5/25 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

      Westport, CT, June 10, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Ferdinand Groenewald to the position of interim Chief Financial Officer.   Personal Bio, Ferdinand Groenewald, age 39Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director

      6/10/24 9:45:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

      Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) or ("BioSig" or "the Company"), a medical technology Company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, today announced the appointment of Mr. Anthony Amato to the Position of Chief Executive Officer ("CEO"), effective immediately.  Additionally, Mr. Amato will serve on the Company's Board of Directors, which is currently being assembled.  Recall, that on April 4, 2024, the Company announced the engagement of Consulting firm, Bridge Associates International Pharmaceutical Consulting ("BAIPC"), led by Mr. Amato.  This corporate action was the natural progressi

      4/30/24 2:03:14 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CFO Groenewald Ferdinand was granted 35,000 shares, increasing direct ownership by 140% to 60,000 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:56 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Amato Anthony N. was granted 23,345 shares, increasing direct ownership by 1% to 2,131,547 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:54 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Abelman Steven Eric was granted 23,345 shares, increasing direct ownership by 29% to 103,345 units (SEC Form 4)

      4 - BioSig Technologies, Inc. (0001530766) (Issuer)

      4/29/25 6:28:47 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care